Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor

被引:41
作者
Ding, XQ
Pinon, DI
Furse, KE
Lybrand, TP
Miller, LJ
机构
[1] Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
[3] Vanderbilt Univ, Dept Chem, Nashville, TN USA
[4] Vanderbilt Univ, Ctr Struct Biol, Nashville, TN USA
关键词
D O I
10.1124/mol.61.5.1041
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insight into the molecular basis of cholecystokinin (CCK) binding to its receptor has come from receptor mutagenesis and photoaffinity labeling studies, with both contributing to the current hypothesis that the acidic Tyr-sulfate-27 residue within the peptide is situated adjacent to basic Arg(197) in the second loop of the receptor. Here, we refine our understanding of this region of interaction by examining a structure-activity series of these positions within both ligand and receptor and by performing three-dimensional molecular modeling of key pairs of modified ligand and receptor constructs. The important roles of Arg(197) and Tyr-sulfate-27 were supported by the marked negative impact on binding and biological response with their natural partner molecule when the receptor residue was replaced by acidic Asp or Glu and when the peptide residue was replaced by basic Arg, Lys, p-amino-Phe, p-guanidino-Phe, or p-methylamino-Phe. Complementary ligand-receptor charge-exchange experiments were unable to regain the lost function. This was supported by the molecular modeling, which demonstrated that the charge-reversed double mutants could not form a good interaction without extensive rearrangement of receptor conformation. The models further predicted that R197D and R197E mutations would lead to conformational changes in the extracellular domain, and this was experimentally supported by data showing that these mutations decreased peptide agonist and antagonist binding and increased nonpeptidyl antagonist binding. These receptor constructs also had increased susceptibility to trypsin degradation relative to the wild-type receptor. In contrast, the relatively conservative R197K mutation had modest negative impact on peptide agonist binding, again consistent with the modeling demonstration of loss of a series of stabilizing inter- and intramolecular bonds. The strong correlation between predicted and experimental results support the reported refinement in the three-dimensional structure of the CCK-occupied receptor.
引用
收藏
页码:1041 / 1052
页数:12
相关论文
共 43 条
[31]  
PEARSON RK, 1987, J BIOL CHEM, V262, P869
[32]  
POWERS SP, 1988, INT J PEPT PROT RES, V31, P429
[33]  
POWERS SP, 1988, J BIOL CHEM, V263, P5295
[34]  
Roettger BF, 1997, MOL PHARMACOL, V51, P357
[35]   DNA SEQUENCING WITH CHAIN-TERMINATING INHIBITORS [J].
SANGER, F ;
NICKLEN, S ;
COULSON, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (12) :5463-5467
[36]  
Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO
[37]  
2-8
[38]   Mutational analysis of the putative devazepide binding site of the CCKA receptor [J].
Smeets, RLL ;
IJzerman, AP ;
Hermsen, HPH ;
Ophorst, OJAE ;
Vries, SEV ;
DePont, JJHHM ;
Willems, PHGM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 325 (01) :93-99
[39]  
STRADER CD, 1991, J BIOL CHEM, V266, P5
[40]   CHARACTERIZATION OF THE 3 DIFFERENT STATES OF THE CHOLECYSTOKININ (CCK) RECEPTOR IN PANCREATIC ACINI [J].
TALKAD, VD ;
PATTO, RJ ;
METZ, DC ;
TURNER, RJ ;
FORTUNE, KP ;
BHAT, ST ;
GARDNER, JD .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1994, 1224 (01) :103-116